Hepatic stellate cells (HSCs) play a critical role in the fibrogenesis of the liver, so they are the target cells of antifibrotic therapy. Activated HSCs, but not quiescent HSCs, express cyclooxygenase-2 (COX-2). The present study was designed to investigate the possible prophylactic and therapeutic effects of a selective COX-2 inhibitor (celecoxib) on liver fibrosis induced by thioacetamide (TAA) in rats. Forty-two male albino rats were divided into five groups: group I, negative control; group II, model of fibrosis; group III, preventive model before induction of fibrosis where celecoxib was given for 4 weeks before TAA; group IV, preventive model at the time of induction of fibrosis where celecoxib was given concomitantly with TAA for 6 weeks; group V, therapeutic model treated after induction of fibrosis. Liver function tests, serum TGF-β1 (ELISA), and histopathological examination of liver sections were performed. Both Metavir and Ishak fibrosis scoring systems were used for the evaluation of fibrosis. Groups III, IV, and V showed significant amelioration of liver function tests and a decrease in serum TGF-β1 as compared to the fibrosis model group (II). Histopathological examination showed the mildest degree of fibrosis in group III. Celecoxib had a hepatoprotective and therapeutic effect against liver damage produced by TAA but with different degrees. The highest efficacy of celecoxib was in the preventive group (III) before time of induction of liver fibrosis, followed by the therapeutic group (V) and then the preventive group (IV) at time of induction of liver fibrosis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Albanis EL, Safadi RL, Friedman SL (2003) Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep 5:48–56
Aydin AF, Kusku-Kiraz Z, Dogru-Abbasoglu S, Gulluoglu M, Uysal M, Kocak-Toker N (2010) Effect of carnosine against thioacetamide-induced liver cirrhosis in rat. Peptides 31:67–71
Bataller R, Brenner D (2005) Liver fibrosis. J Clin Invest 115(2):209–218
Bedossa P, Poynard T (1998) An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperate Study Group. Hepatology 24:289–293
Chávez E, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Castro-Sánchez L, Salazar EP, Moreno MG, Muriel P (2010) Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int 30(7):969–978
Cheng J, Imanishi H, Liu W et al (2002) Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398. Biochem Biophys Res Commun 297:1128–1134
Efsen E, Bonacchi A, Pastacaldi S et al (2001) Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology 33:713–721
Friedman SL (2004) Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1:98–105
Guerra RR, Trotta MR, Parra OM, Avanzo JL, Bateman A (2009) Modulation of extracellular matrix by nutritional hepatotrophic factors in thioacetamide-induced liver cirrhosis in the rat. Braz J Med Biol Res 42:1027–1034
Hu KQ (2003) Cyclooxygenase 2 (COX-2) prostanoid pathway and liver diseases. Prostaglandins Leukot Essent Fatty Acids 69:329–337
Huang HC, Wang SS, Chan CY, Chen YC, Lee FY, Chang FY (2007) Role of hepatic nitric oxide synthases in rats with thioacetamide induced acute liver failure and encephalopathy. J Chin Med Assoc 760:16–23
Hui AY, Dannenberg AJ, Sung JJ et al (2004) Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol 41:251–258
Hui AY, Leung WK, Chan HL et al (2006) Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 26:125–136
Hung KS, Lee TH, Chou WY, Wu CL, Cho CL, Lu CN (2005) Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochem Biophys Res Commun 336:324–331
Ishak KG, Baptista A, Bianchi L (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699
Ismail M, Pinzani M (2009) Reversal of liver fibrosis. Saudi J Gastroenterol 15(1):72–79
Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS (2005) Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl4-induced hepatic fibrosis. World J Gastroenterol 11(8):1141–1148
Jidong C, Toshikazu H (2005) The significance of COX-2 and COX-2 inhibitors in liver fibrosis and liver cancer. Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents 4(2):199–206
Kawamori T, Rao CV, Seibert K et al (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409–412
Kusunoki N, Yamazaki R, Kawai S (2002) Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 46:3159–3167
Lee HS, Huang GT, Chen CH, Chiou LL, Lee CC, Yang PM, Chen DS, Sheu JC (2001) Less reversal of liver fibrosis after prolonged carbon tetrachloride injection. Hepatogastroenterology 48:1312–1315
Leng J, Han C, Demetris AJ et al (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib induced apoptosis. Hepatology 38:756–768
Manea F, Radovan C, Schoonman J (2006) Amperometric determination of thiourea in alkaline media on a copper oxide-copper electrode. J Applied Electrochem 36:1075–1081
Miyazawa K, Moriyama M, Mikuni M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Kaneko M, Shioda A, Tanaka N, Arakawa Y (2003) Analysis of background factors and evaluation of a population at high risk of hepatocellular carcinoma. Intervirology 46:150–156
Mohammed NA, El-Aleem SA, El-Hafiz HA, McMahon RF (2004) Distribution of constitutive (COX-1) and inducible (COX2) cyclooxygenase in postviral human liver cirrhosis. Pathol 57:350–354
Ohayon O, Mawasi N, Pevzner A, Tryvitz A, Gildor T, Pines M, Rojkind M, Paizi M, Spira G (2008) Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats. Lab Invest 88:627–633
Paik Y-H, Kim JK, Lee JI, Kang SH, Kim DY, An SH, Lee SJ, Lee DK, Han K-H, Chon CY, Lee SI, Lee KS, Brenner DA (2009) Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 58:1517–1527
Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK (2004) The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 17:35–38
Wang CH, Jawan B, Lee TH, Hung KS, Chou WY, Lu CN (2004) Single injection of naked plasmid encoding α-melanocyte-stimulating hormone protects against thioacetamide-induced acute liver failure in mice. Biochem Biophys Res Commun 322:153–161
Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM (2007) Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology 46(1):135–140
Yu J, Wu CW, Chu ES (2008) Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 372:571–577
Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV (2008) Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 28(10):1175–1187
About this article
Cite this article
Ftahy, M.M., Latif, N.S.A., Alalkamy, E.F. et al. Antifibrotic potential of a selective COX-2 inhibitor (celecoxib) on liver fibrosis in rats. Comp Clin Pathol 22, 425–430 (2013). https://doi.org/10.1007/s00580-012-1427-4
- COX-2 inhibitors
- Rat liver fibrosis